DNTH
Dianthus Therapeutics Inc.
93.40$
-5.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2.1% | 22.5% | 12.2% | 6.0% | 5.3% | 5.9% | 11.4% | 51.3% | 25.0% | – | 16.4% | – | – | |
| 97.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 83.6% | 100.0% | 96.0% | |
| 861.5% | 1,921.4% | 1,496.3% | 969.9% | 1,176.1% | 1,991.9% | 2,321.8% | 13,601.6% | 8,204.3% | 21,089.8% | 7,457.5% | 6,397.6% | 9,222.6% | |
| 944.0% | 1,013.6% | 645.3% | 321.9% | 300.6% | 515.0% | 630.9% | 4,595.3% | 2,069.4% | 3,496.5% | 2,692.9% | 1,781.5% | 2,318.8% | |
| 1,803.5% | 2,935.0% | 2,141.6% | 1,291.8% | 1,476.6% | 2,506.9% | 2,952.7% | 18,196.9% | 10,273.7% | 24,586.3% | 10,133.9% | 8,179.1% | 11,537.4% | |
| -1,705.5% | -2,835.0% | -2,041.6% | -1,191.8% | -1,376.6% | -2,406.9% | -2,852.7% | -18,096.9% | -10,173.7% | -24,486.3% | -10,050.3% | -8,079.1% | -11,441.4% | |
| -1,597.7% | -2,311.4% | -1,573.0% | -945.1% | -1,159.0% | -2,144.8% | -2,537.5% | -16,388.1% | -9,284.1% | 34,473.6% | -8,819.4% | -6,598.6% | -1,570.9% | |
| -111.1% | 185.6% | -12.2% | – | – | – | – | – | – | – | – | – | – | |
| -1,597.7% | -2,311.4% | -1,573.0% | -945.1% | -1,159.0% | -2,144.8% | -2,537.5% | -16,388.1% | -9,284.1% | 34,473.6% | -8,819.4% | -6,598.6% | -1,570.9% | |
| -1,595.7% | -2,288.8% | -1,560.8% | -939.1% | -1,153.7% | -2,138.9% | -2,526.1% | -16,336.8% | -9,277.3% | 34,564.8% | -8,803.0% | -6,593.7% | -1,549.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.